Flibanserin (Addyi) Dosing in Hepatic Impairment

Why Flibanserin Is Contraindicated in Hepatic Impairment

Flibanserin carries an absolute contraindication in patients with any degree of hepatic impairment. This is not a dose-reduction scenario. The FDA determined that no dosing adjustment could adequately mitigate the safety risk posed by dramatically elevated plasma concentrations in patients with compromised liver function.

The contraindication stems from a dedicated hepatic impairment pharmacokinetic study submitted during the approval process. In subjects with mild hepatic impairment (Child-Pugh class A), flibanserin area under the curve (AUC) increased approximately 4.5-fold compared to healthy controls 1. This magnitude of increase is not correctable through dose reduction. A half-dose (50 mg) would still produce exposure roughly double that of the approved 100 mg dose in a patient with normal liver function, and flibanserin is only manufactured as a 100 mg tablet with no scored breakline.

The FDA did not study flibanserin in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. Given the 4.5-fold rise observed in the mildest category, the agency concluded that exposure in more advanced liver disease would be unacceptably high 1. The prescribing information states: "Flibanserin is contraindicated in patients with hepatic impairment" without qualification by severity grade 1.

How Flibanserin Works: Mechanism of Action

Flibanserin modulates central serotonin and dopamine signaling in brain regions involved in sexual desire. It acts as a full agonist at the serotonin 5-HT1A receptor and an antagonist at the serotonin 5-HT2A receptor, with weaker agonist activity at dopamine D4 receptors 2.

The net pharmacological effect reduces serotonergic inhibition while modestly increasing dopaminergic and noradrenergic tone in the prefrontal cortex. Unlike phosphodiesterase-5 inhibitors used in male sexual dysfunction, flibanserin does not target peripheral blood flow or genital arousal. It works centrally, over weeks of daily dosing, to restore desire circuits that are tonically suppressed in women with HSDD 2.

This CNS mechanism is precisely what makes liver function so critical. Flibanserin already causes dose-dependent reductions in blood pressure and increases in somnolence at approved exposure levels. When hepatic metabolism is impaired and drug concentrations climb several-fold, these pharmacodynamic effects amplify to the point of clinical danger 1.

Pharmacokinetics and the Role of CYP3A4

Understanding why the liver matters here requires a closer look at flibanserin's metabolic pathway. The drug undergoes extensive first-pass hepatic metabolism, with CYP3A4 responsible for the majority of biotransformation and CYP2C19 playing a secondary role 1. Oral bioavailability is approximately 33% in healthy subjects.

When CYP3A4 activity is reduced (as in hepatic impairment), less flibanserin is cleared during first pass and each subsequent elimination half-life. The result is a sharp, non-linear increase in systemic exposure. The 4.5-fold AUC increase seen in mild impairment reflects both higher peak concentrations and a prolonged elimination half-life 1.

This same metabolic vulnerability explains two other major contraindications. Concomitant use of moderate or strong CYP3A4 inhibitors (ketoconazole, itraconazole, fluconazole, clarithromycin, certain HIV protease inhibitors) is also contraindicated because these drugs produce a comparable pharmacokinetic effect to hepatic impairment: they raise flibanserin AUC by 2- to 7-fold depending on the inhibitor 3. CYP2C19 poor metabolizers also show higher exposure, though the increase is less dramatic (approximately 1.5-fold) 1.

The FDA's Clinical Pharmacology review noted: "The increase in flibanserin exposure in subjects with hepatic impairment was considered clinically significant and not manageable through dose adjustment" 4.

Hypotension and Syncope: The Core Safety Concern

The clinical consequence of elevated flibanserin exposure is severe hypotension, sometimes progressing to syncope (fainting). These events represent the primary safety signal that shaped the drug's regulatory history. Flibanserin was rejected by the FDA twice (in 2010 and 2013) before gaining approval in 2015 with a Risk Evaluation and Mitigation Strategy (REMS) program 5.

In a controlled alcohol interaction study, 17% of subjects who combined flibanserin with alcohol required intervention for hypotension or presyncope, and some required placement in the Trendelenburg position for hemodynamic recovery 1. Alcohol, like hepatic impairment, impairs CYP3A4-mediated metabolism and raises flibanserin levels.

In patients with hepatic impairment, the hypotension risk is present even without alcohol. Sustained flibanserin concentrations 4 to 5 times higher than intended produce prolonged vasodilatory effects via central serotonergic and adrenergic mechanisms. Falls, head injuries, and motor vehicle accidents secondary to syncope represent the real-world downstream harms.

Dr. Julia Johnson, former chair of the FDA's Reproductive Health Drugs Advisory Committee, stated during the 2015 advisory meeting: "The risk of hypotension at elevated exposures is not theoretical. We have pharmacodynamic data showing a clear exposure-response relationship for blood pressure reduction with flibanserin" 6.

The REMS Program and Prescriber Responsibilities

Because of the hypotension and syncope risk, flibanserin is available only through the Addyi REMS program. Prescribers must complete certification, and dispensing pharmacies must also be certified. The REMS mandates that prescribers 5:

• Assess for hepatic impairment before writing a prescription
• Verify that the patient is not taking CYP3A4 inhibitors
• Counsel patients to avoid alcohol entirely
• Document the interaction and counseling in the medical record

Failure to screen liver function before prescribing flibanserin is a REMS violation. The certification quiz specifically tests prescribers on the hepatic impairment contraindication.

In 2019, the FDA revised the Addyi label to remove the absolute alcohol contraindication and replace it with a warning, based on postmarketing data showing that moderate alcohol use in real-world settings produced lower rates of hypotension than the controlled study had suggested 5. The hepatic impairment contraindication, by contrast, has never been relaxed.

Clinical Trial Efficacy: What BEGONIA Showed

The BEGONIA trial (N=1,087) randomized premenopausal women with HSDD to flibanserin 100 mg nightly or placebo for 24 weeks 7. The trial demonstrated statistically significant improvements in the co-primary endpoints: satisfying sexual events (SSEs) increased by approximately 0.8 events per month over placebo, and sexual desire as measured by the Female Sexual Function Index (FSFI) desire domain improved by 0.3 points over placebo.

These are modest effect sizes. The clinical relevance of the BEGONIA results (and the other two key trials, DAISY and VIOLET) was debated extensively during the FDA advisory committee process 7. The 2015 advisory committee voted 18-6 in favor of approval, with the majority view holding that a modest benefit was clinically meaningful for a condition with no other FDA-approved pharmacotherapy at the time 6.

Patients with hepatic impairment were excluded from all three key trials. No efficacy data exist for this population, and the contraindication means none will be generated through standard clinical development.

Screening Liver Function Before Prescribing

Because the contraindication is absolute and applies to even mild impairment, prescribers need a practical approach to screening. The following assessments should precede any flibanserin prescription:

Baseline liver function tests (LFTs). Obtain alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, and albumin. Any pattern suggesting hepatic dysfunction warrants further evaluation before prescribing 1.

Clinical history. Ask about known liver disease, including hepatitis B or C, nonalcoholic fatty liver disease (NAFLD/MASLD), alcoholic liver disease, autoimmune hepatitis, and cirrhosis of any etiology. A history of abnormal liver enzymes during prior medication use should prompt caution.

Alcohol use assessment. Heavy alcohol use is both a direct interaction risk and a marker for possible underlying alcoholic liver disease. The label warns against alcohol use with flibanserin 1.

Medication review. Even in patients with normal hepatic function, concurrent CYP3A4 inhibitors are contraindicated. Common offenders include fluconazole (frequently prescribed for vulvovaginal candidiasis), certain macrolide antibiotics, and grapefruit juice in large quantities 3.

If baseline LFTs are elevated, calculate the Child-Pugh score. Any score of 5 or above (class A, B, or C) makes flibanserin contraindicated.

Alternatives for HSDD Patients With Liver Disease

Women with HSDD and hepatic impairment are not without options, though the evidence base is thinner and none of the alternatives carry a specific HSDD indication in this subpopulation.

Bremelanotide (Vyleesi). This melanocortin-4 receptor agonist was approved in 2019 for premenopausal HSDD. It is administered as a subcutaneous injection and is not extensively hepatically metabolized. The prescribing information does not contraindicate use in hepatic impairment, though pharmacokinetic data in this population are limited. In the RECONNECT trials (pooled N=1,247), bremelanotide 1.75 mg increased FSFI desire domain scores by 0.5 points over placebo 8.

Off-label testosterone. Low-dose transdermal testosterone (300 mcg/day) has shown efficacy for HSDD in postmenopausal women across multiple randomized trials, and some clinicians prescribe it off-label for premenopausal women. The Endocrine Society's 2019 position statement noted: "Testosterone therapy can be considered for postmenopausal women with HSDD after a thorough diagnostic workup" 9. Testosterone is also hepatically metabolized, but the transdermal route avoids first-pass hepatic exposure, making it potentially more suitable for patients with mild liver dysfunction.

Psychotherapy. Cognitive behavioral therapy (CBT) and mindfulness-based interventions have demonstrated improvements in sexual desire in controlled trials and carry no hepatotoxic risk 10.

The choice among these options should be individualized based on the patient's degree of hepatic impairment, comorbid conditions, and treatment goals.

Common Prescribing Errors to Avoid

Several preventable errors have been documented in flibanserin prescribing:

Prescribing without LFTs. The most straightforward violation. A 2020 pharmacovigilance review found that prescriber adherence to the REMS pre-treatment checklist was inconsistent in the first years after approval 5.

Assuming "mild" impairment is safe. The word "mild" may mislead prescribers into thinking a dose adjustment is possible. It is not. Child-Pugh A is the mildest category, and it produces a 4.5-fold exposure increase 1.

Missing CYP3A4 inhibitor co-prescriptions. A patient with normal liver function who takes fluconazole 200 mg for a yeast infection is pharmacokinetically similar to a patient with hepatic impairment. Both scenarios produce dangerous flibanserin accumulation 3.

Failing to reassess liver function over time. A patient who had normal LFTs at flibanserin initiation may develop hepatic dysfunction months or years later (e.g., from new MASLD, hepatitis, or alcohol use). Periodic reassessment is clinically appropriate, though the label does not specify an interval.

Key Pharmacokinetic Parameters at a Glance

Flibanserin's pharmacokinetic profile in healthy subjects includes: time to peak concentration (Tmax) of 0.75 to 1 hour with food (faster in fasting state), elimination half-life of approximately 11 hours, volume of distribution of approximately 980 L (indicating extensive tissue distribution), and protein binding of approximately 98% 1. In hepatic impairment, the prolonged half-life and reduced first-pass clearance compound to produce sustained supratherapeutic concentrations through the dosing interval.

The recommended dosing in patients with normal liver function is 100 mg orally once daily at bedtime. Bedtime administration reduces the risk of hypotension-related events during waking hours. If a patient does not notice improvement in HSDD symptoms after 8 weeks, the drug should be discontinued 1.